RU2016147351A3 - - Google Patents

Download PDF

Info

Publication number
RU2016147351A3
RU2016147351A3 RU2016147351A RU2016147351A RU2016147351A3 RU 2016147351 A3 RU2016147351 A3 RU 2016147351A3 RU 2016147351 A RU2016147351 A RU 2016147351A RU 2016147351 A RU2016147351 A RU 2016147351A RU 2016147351 A3 RU2016147351 A3 RU 2016147351A3
Authority
RU
Russia
Application number
RU2016147351A
Other versions
RU2744836C2 (ru
RU2016147351A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2016147351A publication Critical patent/RU2016147351A/ru
Publication of RU2016147351A3 publication Critical patent/RU2016147351A3/ru
Application granted granted Critical
Publication of RU2744836C2 publication Critical patent/RU2744836C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053Skin, nerves, brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/535Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2474/00Immunochemical assays or immunoassays characterised by detection mode or means of detection
    • G01N2474/20Immunohistochemistry assay
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
RU2016147351A 2014-05-08 2015-05-07 Прямой иммуногистохимический анализ RU2744836C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461990111P 2014-05-08 2014-05-08
US61/990,111 2014-05-08
PCT/US2015/029762 WO2015171938A1 (en) 2014-05-08 2015-05-07 Direct immunohistochemistry assay

Publications (3)

Publication Number Publication Date
RU2016147351A RU2016147351A (ru) 2018-06-09
RU2016147351A3 true RU2016147351A3 (ru) 2018-12-27
RU2744836C2 RU2744836C2 (ru) 2021-03-16

Family

ID=54393016

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016147351A RU2744836C2 (ru) 2014-05-08 2015-05-07 Прямой иммуногистохимический анализ

Country Status (8)

Country Link
US (1) US11474101B2 (ru)
EP (1) EP3140653B1 (ru)
JP (1) JP6875129B2 (ru)
CN (1) CN106415269B (ru)
AU (1) AU2015255883A1 (ru)
DK (1) DK3140653T3 (ru)
RU (1) RU2744836C2 (ru)
WO (1) WO2015171938A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3011817A1 (en) * 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CA3099487A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag Human antibodies binding to ror2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CN112236677A (zh) * 2018-02-09 2021-01-15 贵州美鑫达医疗科技有限公司 直接免疫组织化学和免疫细胞化学方法
JP6719117B2 (ja) * 2018-03-27 2020-07-08 国立大学法人京都大学 免疫チェックポイント阻害剤の奏効性の判定を補助する方法、試薬キット、装置及びコンピュータプログラム
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CN109116032B (zh) * 2018-08-01 2021-09-03 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) 用于检测***癌患者pd-l1抗体免疫治疗及预后的试剂盒
US20210332405A1 (en) 2018-10-02 2021-10-28 Osler Diagnostics Limited Methods for immunoassays using electrochemical measurement
CN109781983A (zh) * 2019-03-14 2019-05-21 武汉原谷生物科技有限责任公司 一种多聚酶法快速免疫组化试剂盒及其免疫组化方法
EP4105238A4 (en) 2020-02-10 2024-03-27 Shanghai Escugen Biotechnology Co Ltd CLAUDIN 18.2 ANTIBODIES AND THEIR USE
EP4124622A1 (en) * 2021-07-29 2023-02-01 Fondazione IRCCS Istituto Nazionale dei Tumori Rapid histological diagnosis for oncology therapy
CN114113605B (zh) * 2021-11-04 2022-11-11 贵州美鑫达医疗科技有限公司 用于脑瘤术中快速免疫组化的多聚酶-抗体组合
CN115586335B (zh) * 2021-11-04 2023-10-13 贵州美鑫达医疗科技有限公司 用于黑素瘤术中快速免疫组化的多聚酶-抗体组合
CN114113616B (zh) * 2021-12-07 2022-08-23 深圳裕策生物科技有限公司 一种试剂盒及其染色方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4687732A (en) * 1983-06-10 1987-08-18 Yale University Visualization polymers and their application to diagnostic medicine
US4657853A (en) 1984-09-14 1987-04-14 E. I. Du Pont De Nemours And Company Immunoassays utilizing covalent conjugates of polymerized enzyme and antibody
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6027874A (en) * 1995-01-23 2000-02-22 Pasteur Sanofi Diagnostics Immunoenzymatic conjugate, method for its productions, applications thereof
FR2734365B1 (fr) * 1995-05-18 1999-04-09 Pasteur Sanofi Diagnostics Conjugue immunoenzymatique, son procede de preparation et ses applications
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2225852C (en) * 1995-06-30 2009-04-14 Mochida Pharmaceutical Co., Ltd. Anti-fas ligand antibody and assay method using the anti-fas ligand antibody
JP3781934B2 (ja) 1999-12-22 2006-06-07 株式会社ニチレイバイオサイエンス 酵素−タンパク質複合体
WO2003104424A2 (en) * 2002-06-10 2003-12-18 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Novel molecular conjugates for signal amplification
AU2003290479A1 (en) * 2002-08-21 2004-03-11 Arcturus Engineering, Inc. Preservation of rna quality and content in tissue sections during immunohistochemistry
US20050026196A1 (en) * 2003-06-23 2005-02-03 Centre Hospitalier Universitaire De Montreal Prognostic marker for prostate cancer and methods and kits for using same
DE602004026341D1 (de) * 2003-11-04 2010-05-12 Bayer Pharmaceuticals Corp IMMUNOHISTOCHEMISCHE VERFAHREN ZUR ÜBERWACHUNG VON pERK SPIEGELN
JP4949038B2 (ja) 2003-12-01 2012-06-06 ダコ デンマーク アクティーゼルスカブ 免疫組織化学的検出のための方法および組成物
AU2006239154A1 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc Nanoparticle conjugates
AU2006239315B2 (en) * 2005-04-28 2012-03-01 Ventana Medical Systems, Inc. Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
EP1943354A2 (en) * 2005-10-21 2008-07-16 Monaliza Medical Ltd. Methods and kits for analyzing genetic material of a fetus
ES2804129T3 (es) * 2005-11-23 2021-02-03 Ventana Med Syst Inc Conjugado anticuerpo-enzima
US20080026366A1 (en) * 2006-06-07 2008-01-31 Newcomer Supply, Inc. Biological fixative and method of using the biological fixative
CN1945333A (zh) * 2006-09-28 2007-04-11 孙爱静 乳腺癌***转移快速免疫组化检测试剂及其检测方法
EP2095117A2 (en) * 2006-12-01 2009-09-02 Dako Denmark A/S Systems and methods for biological and chemical detection, comprising automatic selection of reagent sets
WO2010078376A2 (en) 2008-12-30 2010-07-08 Ventana Medical Systems, Inc. Fc-specific polymer-conjugated antibodies and their diagnostic use
CN102574925A (zh) * 2009-03-26 2012-07-11 昆腾免疫有限公司 用于诊断及临床应用的癌胚胎抗原/未成熟层粘连蛋白受体抗体
US9541504B2 (en) * 2010-08-05 2017-01-10 Cambridge Research & Instrumentation, Inc. Enhancing visual assessment of samples
ES2663556T3 (es) * 2011-07-15 2018-04-13 Eisai R&D Management Co., Ltd. Anticuerpos frente al receptor alfa del folato y usos de los mismos
CN102590512A (zh) * 2012-02-17 2012-07-18 博生吉医药科技(苏州)有限公司 一种乳腺癌个体化用药检测试剂盒及其使用方法

Also Published As

Publication number Publication date
JP6875129B2 (ja) 2021-05-19
EP3140653B1 (en) 2022-05-11
EP3140653A4 (en) 2018-03-21
US11474101B2 (en) 2022-10-18
WO2015171938A1 (en) 2015-11-12
CN106415269A (zh) 2017-02-15
AU2015255883A1 (en) 2016-10-27
US20170074867A1 (en) 2017-03-16
DK3140653T3 (da) 2022-06-20
CN106415269B (zh) 2020-11-27
RU2744836C2 (ru) 2021-03-16
JP2017515121A (ja) 2017-06-08
RU2016147351A (ru) 2018-06-09
EP3140653A1 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
BR112016025888A2 (ru)
BR112016016478A2 (ru)
RU2016147351A3 (ru)
BR112016030815A2 (ru)
BR112016021082A2 (ru)
BR112016022077A2 (ru)
BR112016027060A2 (ru)
BR112016023151A2 (ru)
BR112016015819A2 (ru)
BR112016023457A2 (ru)
BR112016018749A2 (ru)
BR112016021581A2 (ru)
BR112016030327A2 (ru)
BR112016014009A2 (ru)
BR112016016075A2 (ru)
BR112016015451A2 (ru)
BR112016019374A2 (ru)
CN302729512S (ru)
CN302719845S (ru)
CN302734128S (ru)
CN302733153S (ru)
CN302731786S (ru)
CN302730044S (ru)
CN302729559S (ru)
CN302734482S (ru)